NICE has received an appeal, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations: ...

About 90% of patients with CDKL5 deficiency disorder (CDD) are girls. CDD patients suffer from seizures that usually begin within the first few months of life, as well as from profound ...

In addition to its work on a treatment for a second rare neurodevelopmental disease, CDKL5-deficiency disorder (CDD), Vyant Bio is developing Parkinson’s disease and Alzheimer’s disease models.

Marinus Pharmaceuticals, a company based in Radnor that focuses on therapies for seizures, is laying off nearly half of its workforce after disappointing results from a clinical trial. On Tuesday, the ...

People with CDKL5 deficiency disorder (CDD) now have their first FDA-approved treatment, after the US regulator gave the nod to Marinus Pharma's Ztalmy for the rare genetic form of epilepsy.

is a pharmaceutical company focused on developing innovative treatments for seizure disorders, with a key product, ZTALMY (ganaxolone), an FDA-approved oral suspension for CDKL5 deficiency disorder.

As it stands, Ztalmy is approved in an oral suspension formulation for patients with seizures associated with CDKL5 deficiency disorder (CDD) following its FDA nod in 2022. Since the approval ...

This patent, numbered 12,115,169, extends through September 2042 and encompasses treatments for various epilepsy disorders ...